Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, TD Cowen Analyst Says

Protagonist Therapeutics (NASDAQ:PTGX) had its target price raised by analysts at TD Cowen from $90.00 to $100.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. TD Cowen’s price target points to a potential upside of 8.60% from the company’s current price.

Several other brokerages have also recently commented on PTGX. JPMorgan Chase & Co. boosted their target price on Protagonist Therapeutics from $68.00 to $81.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Weiss Ratings downgraded Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, February 17th. Truist Financial upped their price objective on Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a report on Monday, January 5th. HC Wainwright lifted their target price on Protagonist Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Finally, Citigroup boosted their price target on shares of Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $99.31.

Protagonist Therapeutics Stock Up 4.2%

Shares of PTGX opened at $92.08 on Thursday. The firm has a 50-day moving average price of $84.24 and a 200 day moving average price of $76.86. The firm has a market capitalization of $5.88 billion, a PE ratio of -44.92 and a beta of 2.26. Protagonist Therapeutics has a 52-week low of $35.97 and a 52-week high of $96.54.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.16). The company had revenue of $7.44 million for the quarter, compared to the consensus estimate of $14.92 million. Protagonist Therapeutics had a negative return on equity of 19.50% and a negative net margin of 282.83%. On average, equities analysts expect that Protagonist Therapeutics will post 2.43 EPS for the current year.

Insider Activity at Protagonist Therapeutics

In related news, insider Arturo Md Molina sold 5,000 shares of Protagonist Therapeutics stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $82.00, for a total value of $410,000.00. Following the transaction, the insider owned 84,115 shares of the company’s stock, valued at approximately $6,897,430. This trade represents a 5.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Asif Ali sold 46,203 shares of the business’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $83.13, for a total value of $3,840,855.39. Following the sale, the chief financial officer owned 60,320 shares in the company, valued at approximately $5,014,401.60. The trade was a 43.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 203,167 shares of company stock valued at $16,889,199 over the last ninety days. Company insiders own 4.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Farallon Capital Management LLC raised its holdings in shares of Protagonist Therapeutics by 0.4% during the third quarter. Farallon Capital Management LLC now owns 6,196,006 shares of the company’s stock valued at $411,601,000 after acquiring an additional 24,000 shares during the period. Vanguard Group Inc. grew its position in Protagonist Therapeutics by 27.2% during the 4th quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock worth $472,832,000 after purchasing an additional 1,156,461 shares in the last quarter. BVF Inc. IL raised its stake in Protagonist Therapeutics by 24.7% during the 2nd quarter. BVF Inc. IL now owns 3,211,041 shares of the company’s stock valued at $177,474,000 after purchasing an additional 636,026 shares during the period. State Street Corp raised its stake in Protagonist Therapeutics by 18.5% during the 2nd quarter. State Street Corp now owns 3,207,543 shares of the company’s stock valued at $177,281,000 after purchasing an additional 500,924 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in shares of Protagonist Therapeutics by 66.2% in the fourth quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock valued at $276,992,000 after purchasing an additional 1,262,977 shares in the last quarter. 98.63% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Protagonist Therapeutics

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: Barclays raised its price target on PTGX from $108 to $113 and maintained an “overweight” rating — a sizable upside signal from a major bank that supports continued buying interest. Article Title
• Positive Sentiment: Citizens JMP bumped its target from $102 to $112 with a “market outperform” call, reinforcing bullish analyst sentiment and adding short-term demand pressure. Article Title
• Positive Sentiment: TD Cowen raised its price target from $90 to $100 and kept a “buy” stance — another price-target lift that supports upward momentum. Article Title
• Positive Sentiment: HC Wainwright materially raised its FY2026 EPS view (to $4.18 from $3.40) and sharply lifted Q3 2026 EPS to $3.60 (from $0.05), while reiterating a “Buy” rating and a $117 target — a near-term earnings upgrade that investors may view as validation of upcoming revenue/catalyst expectations.
• Neutral Sentiment: Coverage roundup: a Benzinga piece summarizes analyst views across eight firms, useful for context but not a direct catalyst. A Glimpse Into The Expert Outlook
• Negative Sentiment: HC Wainwright also cut several longer-term and quarter-specific estimates: Q4 2026 EPS was lowered sharply to ($0.71) from $2.04, FY2027 and FY2028 forecasts were reduced (to -$2.06 and -$2.08 respectively), and FY2029/FY2030 targets were trimmed dramatically — signaling greater model uncertainty and potential volatility in multi-year expectations.
• Negative Sentiment: Smaller cuts: HC Wainwright nudged Q2 2026 EPS down to $1.98 from $2.03 and trimmed FY2029/FY2030 estimates significantly — these revisions highlight sensitivity in the firm’s forecasting and could temper enthusiasm if investors focus on the downgraded out-years.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.